Clinical Trial Update: TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating TAS-102 with bevacizumab and tislelizumab in third-line or earlier for colorectal cancer with liver metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Liver Metastasis

Drugs mentioned

• Bevacizumab (bevacizumab)
• TAS-102 (trifluridine/tipiracil)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Immunotherapy, Colorectal Cancer | Phase 2 | Status: UNKNOWN